TScan Therapeutics
Founded 2018 · CIK 0001783328 · Biotech · Public
Platform for discovering T-cell receptor and target pairs to develop cancer immunotherapies
tscan.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $123M
- 2 Form D · Jan 2021
- 69 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 0 granted · 40 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $23,300,000 | |
| Private capital raised | Form D · SEC | $100,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1252 | Escape Bio | — | $124M |
| 1253 | B-TECH CONSULTING, LTD | — | — |
| 1254 | MIND BIOSCIENCES LLC | — | — |
| 1255 | TScan Therapeutics | — | $123M |
| 1256 | Aardvark Therapeutics, Inc. | — | $103M |
| 1257 | Satellite Biosciences, Inc. | — | $101M |
| 1258 | GPN THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Timothy BarberichDirector
- Robert CraneExecutive Officer
- Doug FambroughDirector
- Lea HachigianDirector
- Ittai HarelDirector
- Andrew HedinDirector
- Steve KrausDirector
- Campbell MurrayDirector
- Nandita ShangariDirector
- Brian SilverDirector
- Hannes SmarasonDirector
- David SouthwellDirector · Executive Officer
- Christoph WestphalDirector
Patents
- Multiplexed T Cell Receptor Compositions, Combination Therapies, And Uses Thereofapplication
- Prame Immunogenic Peptides, Binding Proteins Recognizing Prame Immunogenic Peptides, And Uses Thereofapplication
- Binding Proteins Recognizing HA-2 Antigen And Uses Thereofapplication
- Binding Proteins Recognizing HA-1 Antigen And Uses Thereofapplication
- Compositions And Methods For Identifying Epitopesapplication
- Binding Proteins Recognizing HPV16 E7 Antigen And Uses Thereofapplication
- MAGEA1 Immunogenic Peptides, Binding Proteins Recognizing MAGEA1 Immunogenic Peptides, And Uses Thereofapplication
- Binding Proteins Recognizing CD45 Immunogenic Peptides And Uses Thereofapplication
- Use Of Binding Proteins For Treatment Of Solid Tumorsapplication
- Use Of ANTI-HA-1 And ANTI-HA-2 Binding Proteins For Treatment Of Aml, All, And Mdsapplication
- Binding Proteins Recognizing MAGEA4 Immunogenic Peptides And Uses Thereofapplication
- Use Of ANTI-HA-1 And ANTI-HA-2 Binding Proteins For Treatment Of Aml, All, And Mdsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.